Cubist Systematic Strategies LLC Makes New $55,000 Investment in Allakos Inc. (NASDAQ:ALLK)

Cubist Systematic Strategies LLC acquired a new position in shares of Allakos Inc. (NASDAQ:ALLK) in the 2nd quarter, HoldingsChannel reports. The firm acquired 55,486 shares of the company’s stock, valued at approximately $55,000.

Several other large investors also recently bought and sold shares of ALLK. Point72 DIFC Ltd purchased a new stake in shares of Allakos in the second quarter valued at approximately $25,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Allakos in the second quarter valued at approximately $112,000. BNP Paribas Financial Markets grew its position in shares of Allakos by 1,041.1% in the first quarter. BNP Paribas Financial Markets now owns 205,663 shares of the company’s stock valued at $259,000 after purchasing an additional 187,640 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Allakos in the first quarter valued at approximately $929,000. Finally, Ikarian Capital LLC grew its position in shares of Allakos by 293.4% in the first quarter. Ikarian Capital LLC now owns 932,675 shares of the company’s stock valued at $1,175,000 after purchasing an additional 695,619 shares in the last quarter. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

Allakos Stock Performance

ALLK opened at $0.66 on Thursday. Allakos Inc. has a one year low of $0.54 and a one year high of $3.41. The stock has a market capitalization of $58.30 million, a PE ratio of -0.27 and a beta of 1.16. The business’s 50 day moving average price is $0.65 and its 200 day moving average price is $0.93.

Allakos (NASDAQ:ALLK) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.02. As a group, equities research analysts forecast that Allakos Inc. will post -1.2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on ALLK shares. Jefferies Financial Group dropped their price target on Allakos from $1.50 to $1.00 and set a “hold” rating for the company in a research report on Thursday, July 18th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Allakos in a report on Thursday, June 20th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $3.00 price objective on shares of Allakos in a report on Thursday, September 26th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat, Allakos currently has an average rating of “Hold” and a consensus target price of $1.67.

Allakos Profile

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.